Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZBTB2 pseudogene 1 (ZBTB2P1) is classified as a pseudogene and does not appear to encode a functional protein. Its canonical gene, ZBTB2, is a zinc finger and BTB domain-containing transcription factor involved in chromatin remodeling, DNA methylation-sensitive gene regulation, and stem cell differentiation. ZBTB2 has reported roles in cancer biology, especially in relation to p53 function and hypoxia signaling; however, there is no evidence that the pseudogene itself is expressed, has biological activity, or acts as a drug target. As such, "ZBTB2P1" is not considered a therapeutic target, nor does it have recognized aliases, disease associations, or bioactivity—its inclusion as a drug target is incorrect. The designation "ZBTB2P1" correctly refers to a pseudogene, not a functional molecule or receptor, and therefore does not meet the criteria for a therapeutic target. If information about the functional ZBTB2 protein is needed, refer instead to "Zinc finger and BTB domain-containing protein 2 (ZBTB2)".
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZBTB2 pseudogene 1 (ZBTB2P1).